WHO WE ARE
Allterum Therapeutics, Inc., is a biopharmaceutical company targeting the IL-7 pathway for the treatment of IL-7R expressing cancers. Allterum was founded in 2018 by Fannin in Houston, TX.

OUR FOCUS
Why Allterum Therapeutics
Our Partnerships & Collaborators

”After years of searching for a way to help those kids who have no effective treatment for their leukemia, I’m thrilled to see Allterum take our antibody into the clinic.”
Scott Durum, Ph.D.
Inventor | Cytokine and Immunity Section | National Cancer Institute


``I am excited to work with Allterum to develop a much-needed option for the treatment of children with T-cell ALL.``
Eric Shafer, M.D., M.H.S
Assist. Professor, Pediatrics-Oncology | Texas Children's Hospital & Baylor College of Medicine


``I am excited to work with Allterum to develop a much-needed option for the treatment of children with T-cell ALL.``
Eric Schafer, M.D., M.H.S.
Assist. Professor, Pediatrics-Oncology | Texas Children's Hospital & Baylor College of Medicine


”After years of searching for a way to help those kids who have no effective treatment for their leukemia, I’m thrilled to see Allterum take our antibody into the clinic.”
Scott Durum, Ph.D.
Inventor | Cytokine and Immunity Section | National Cancer Institute

Allterum is a Fannin company.
Fannin is Houston's most active early-stage life sciences development group with the primary focus being on development of early stage assets, in partnership with our academic collaborators. The studio’s assets include internally developed assets like Brevitest and in-licensed assets from academic institutions including local Houstonian institutions such as MD Anderson Cancer Center, Baylor College of Medicine, Rice University, Houston Methodist, Texas A&M, Texas Children’s, University of Texas, and University of Houston.
Stay Up To Date
ALLTERUM THERAPEUTICS
Advancing an innovative solution for a critical and unmet medical need